Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M854Revenue (TTM) $M1.3Net Margin (%)-17,417.5Altman Z-Score-2.2
Enterprise Value $M746EPS (TTM) $-5.0Operating Margin %-17,400.2Piotroski F-Score1
P/E(ttm)--Beneish M-Score-1.3Pre-tax Margin (%)-17,417.5Higher ROA y-yN
Price/Book6.110-y EBITDA Growth Rate %2.4Quick Ratio2.9Cash flow > EarningsY
Price/Sales6225-y EBITDA Growth Rate %36.1Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-95.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-133.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.8ROIC % (ttm)-627.5Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 18.319%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 18.31-19%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 18.31-42%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 18.31-28%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 18.31-38%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 18.31-52%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 18.31-36%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 18.31-32%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.46)
$ 18.31183%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.94)
$ 18.31271%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 18.31133%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 18.3189%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.2812.47view
Barry RichardDirector 2016-03-14Buy75,000$15.6616.92view
Price Ben GilDirector 2016-03-14Buy4,500$16.79.64view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.8254.91view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.8254.91view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9531.25view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5645.78view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-50.57view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-47.64view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-43.97view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 28 2016
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June... Jun 28 2016
​Why Sarepta just made its soon-to-begin drug trial even longer Jun 27 2016
Still Little Hope Of FDA Approval For Sarepta, SunTrust Says Sell Jun 27 2016
Sarepta Therapeutics: Radio Silence Jun 23 2016
Sarepta Push for Duchenne Drug Approval Helped by Clinical Trial Changes Jun 23 2016
Summit Therapeutics PLC (ADR) (SMMT) Is Hot On Sarepta Therapeutics Inc (SRPT)’s DMD Tail Jun 21 2016
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June... Jun 17 2016
Sarepta seen holding onto recent gains Jun 14 2016
3 Biotechs That Just Announced Successful Phase 2 Trials Jun 11 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 10 2016
Sarepta Therapeutics: And Now We Wait Jun 10 2016
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week Jun 10 2016
Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too Jun 10 2016
Sarepta (SRPT) Stock Spikes on $37.5 Million Stock Offering Jun 09 2016
Sarepta: Why So Little? Jun 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)